Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02509065 · ClinicalTrials.gov registry record · NA

The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance

A NA study of Type 2 Diabetes and Type 1 Diabetes, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT02509065 is a NA study of Type 2 Diabetes and Type 1 Diabetes that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02509065, a NA study of Type 2 Diabetes and Type 1 Diabetes, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The current study is designed to determine the effect on mean glucose, hypoglycemia, glucagon usage, and insulin usage of adjusting upward the glucose target of the bi-hormonal bionic pancreas, and determine whether there is a target at which adequate glycemic control is achieved by an insulin-only bionic pancreas with minimal hypoglycemia.

Interventions

  • OTHER Usual Care
  • DEVICE Bionic Pancreas

Study Locations (1)

Massachusetts

  • Masscahusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-08
Est. Completion 2017-12
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02509065

The ClinicalTrials.gov registry entry for NCT02509065 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT02509065 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02509065 about?

NCT02509065 is a clinical study titled "The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance". The current study is designed to determine the effect on mean glucose, hypoglycemia, glucagon usage, and insulin usage of adjusting upward the glucose target of the bi-hormonal bionic pancreas, and determine whether there is a target at which adequate glycemic control is achieved by an insulin-only ...

What is the current status of trial NCT02509065?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-08. Estimated completion is 2017-12.

What conditions does trial NCT02509065 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Type 1 Diabetes.

What interventions are being tested in trial NCT02509065?

The interventions under investigation include: Usual Care (OTHER), Bionic Pancreas (DEVICE).

Who is sponsoring clinical trial NCT02509065?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02509065 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.